2024
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Murphy S, Goodrich E, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal Of Medicine 2024, 390: 1770-1780. PMID: 38587249, DOI: 10.1056/nejmoa2402309.Peer-Reviewed Original ResearchConceptsNon-HDL cholesterolElevated cardiovascular riskLevels of triglyceridesTriglyceride levelsCardiovascular riskModerate hypertriglyceridemiaApolipoprotein BAdverse eventsNon-high-density lipoprotein (HDL) cholesterolLow-density lipoprotein (LDL) cholesterolBaseline to 6 monthsMedian triglyceride levelsRisk of adverse eventsLDL cholesterol levelsHigh cardiovascular riskTriglyceride-rich lipoproteinsApolipoprotein C-IIISevere hypertriglyceridemiaMedian ageTriglyceride loweringPlatelet abnormalitiesNo significant changesPlaceboPhase 2bPrimary outcome
2022
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
Sposito A, Breder I, Barreto J, Breder J, Bonilha I, Lima M, Oliveira A, Wolf V, Luchiari B, do Carmo H, Munhoz D, Oliveira D, Coelho-Filho O, Coelho O, Matos-Souza J, Moura F, de Carvalho L, Nadruz W, Quinaglia T, Kimura-Medorima S. Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial. Cardiovascular Diabetology 2022, 21: 147. PMID: 35933413, PMCID: PMC9356512, DOI: 10.1186/s12933-022-01584-8.Peer-Reviewed Original ResearchConceptsFlow-mediated dilationEndothelial functionPost-treatment changesPlasma levelsPlasma levels of nitric oxide metabolitesBackgroundSodium-glucose cotransporter 2 inhibitorsCardiovascular eventsInhibitors reduce cardiovascular eventsLevels of nitric oxide metabolitesE groupPlasma levels of nitrateEE groupHigh-risk patientsProprotein convertase subtilisin/kexin 9Nitric oxide metabolitesRandomized active-controlled trialActive-controlled trialReduce cardiovascular eventsType 2 diabetesPCSK9-iSGLT2i treatmentPrimary endpointSGLT2-iEndothelial dysfunctionSecondary outcomesTirzepatide for diabetes: on track to SURPASS current therapy
Moura F, Scirica B, Ruff C. Tirzepatide for diabetes: on track to SURPASS current therapy. Nature Medicine 2022, 28: 450-451. PMID: 35260841, DOI: 10.1038/s41591-022-01733-2.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesDiabetes MellitusGastric Inhibitory PolypeptideHumansHypoglycemic Agents
2020
A current review of COVID-19 for the cardiovascular specialist
Lang J, Wang X, Moura F, Siddiqi H, Morrow D, Bohula E. A current review of COVID-19 for the cardiovascular specialist. American Heart Journal 2020, 226: 29-44. PMID: 32497913, PMCID: PMC7252118, DOI: 10.1016/j.ahj.2020.04.025.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine MonophosphateAlanineAntimalarialsAntiviral AgentsBetacoronavirusBiomarkersCardiovascular DiseasesChloroquineCoronavirus InfectionsCOVID-19HumansHydroxychloroquineHypoxiaPandemicsPlasmaPneumonia, ViralReceptor, Angiotensin, Type 2Risk FactorsSARS-CoV-2Takotsubo CardiomyopathyVirus InternalizationConceptsAcute cardiac injuryCardiac injuryAdverse outcomesLevels of cardiac troponinAssociated with adverse outcomesHyperinflammatory cytokine stormType 2 myocardial infarctionPre-existing cardiovascular diseaseLevel of suspicionComplications of COVID-19Stress-related cardiomyopathyIncreased blood levelsCardiovascular risk factorsNonischemic myocardial injurySevere COVID-19Cardiovascular complications of COVID-19Nonischemic causesTakotsubo syndromeNatriuretic peptideD-dimerHigher mortality riskCardiovascular complicationsDiffuse thrombosisInflammatory milieuMyocardial dysfunction
2019
Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
Cintra R, Moura F, Carvalho L, Barreto J, Tambascia M, Pecoits-Filho R, Sposito A. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Revista Da Associação Médica Brasileira 2019, 65: 70-86. PMID: 30758423, DOI: 10.1590/1806-9282.65.1.70.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsRisk of hypoglycemiaAntidiabetic therapySodium-glucose co-transporter 2High risk of hypoglycemiaIncreased risk of hypoglycemiaPrevalence of type 2 diabetes mellitusType 2 diabetes mellitusRenal proximal convoluted tubulesChronic kidney diseaseCo-morbid diseasesSystolic blood pressurePost hoc studyProximal convoluted tubulesReduced insulin sensitivitySGLT2i therapyMedian ageSodium-glucoseSodium reabsorptionOlder individualsClinical trialsIncreased riskKidney diseaseBlood pressureConvoluted tubules
2012
Emergent cardiovascular risk factors in the very elderly
Moura F, Freitas W, Sposito A. Emergent cardiovascular risk factors in the very elderly. Expert Review Of Cardiovascular Therapy 2012, 10: 1221-1225. PMID: 23190062, DOI: 10.1586/erc.12.98.Peer-Reviewed Original Research